Drug Profile
Research programme: neurological disorders kinase inhibitors - Arrien Pharmaceuticals
Alternative Names: ARN-1104; ORS 1006; ORS 1104Latest Information Update: 28 Sep 2018
Price :
$50
*
At a glance
- Originator Oros Pharmaceuticals
- Developer Arrien Pharmaceuticals
- Class Small molecules
- Mechanism of Action DYRK kinase inhibitors; LRRK2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Parkinson's disease
Highest Development Phases
- No development reported Parkinson's disease
- Discontinued Alzheimer's disease; Down syndrome
Most Recent Events
- 28 Sep 2018 No recent reports of development identified for preclinical development in Parkinson's-disease in USA (PO)
- 09 Sep 2016 Discontinued - Preclinical for Alzheimer's disease in USA (PO)
- 09 Sep 2016 Discontinued - Preclinical for Down syndrome in USA (PO)